echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > PD-1 monoantivo combined with beret meth and chemotherapy: significantly improved progression-free survival in patients with non-small cell lung cancer.

    PD-1 monoantivo combined with beret meth and chemotherapy: significantly improved progression-free survival in patients with non-small cell lung cancer.

    • Last Update: 2020-08-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Japan's Ono Pharmaceutical Co., Ltd. announced that PD-1 monoantiphone Opdivo (nivolumab) combined anti-VEGF (vascular endoder growth factor) mono-bevacizumab and chemotherapy, treatment of non-small cell lung cancer Phase III clinical success.
    Image source: Picture Source: In the ONO-4538-52/TASUKI-52 study, the Opdivo combination group (n s 275) was compared with a simple placebo combined with beva monotherapy and chemotherapy (placebo group: n s 275) in patients with IIIB/IV stage or recurrent non-squamous non-small cell lung cancer who were not suitable for radiotherapy.
    analysis showed that the Opdivo group showed significant statistical improvement in the main endpoints of progression-free survival (PFS) compared to the placebo group, and no new safety issues were identified.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.